CERT
Certara
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 2
Sell signal 1
consensus rating "Buy"
Revenue Beats Expectation
EPS Below Expectations
Key Stats
--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
About CERT
Certara, Inc.
A global leader in biosimulation
4 Radnor Corporate Center, Suite 350, Radnor, Pennsylvania 19087
--
Certara, Inc., was incorporated in Delaware on June 27, 2017. The company utilizes biosimilar software and technology to accelerate the delivery of medicines to patients to transform the discovery and development of traditional medicines. Biosimulation is a powerful technique for conducting virtual trials with virtual patients to better understand the role of drugs in different individuals. Biopharmaceutical companies use their proprietary biosimilar software throughout the drug development process to inform critical decisions, which not only saves a lot of time and money, but also improves the safety and effectiveness of drugs, improving the lives of millions of people every year.
Company Financials
EPS
CERT has released its 2024 Q4 earnings. EPS was reported at 0.15, versus the expected 0.13, beating expectations. The chart below visualizes how CERT has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
CERT has released its 2024 Q4 earnings report, with revenue of 100.36M, reflecting a YoY change of 14.03%, and net profit of 6.58M, showing a YoY change of 152.80%. The Sankey diagram below clearly presents CERT’s revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
